$MLTX SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Other Events On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the trea...
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
14 Aug 2026	SCHEDULE 13G/A
10 Aug 2026	REGISTRATION STATEMENT
10 Aug 2026	REGISTRATION STATEMENT
10 Aug 2026	10-Q
10 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
29 Jul 2026	Form 4: Reich Kristian, Chief Scientific Officer Sold 1,100 shares ($22K)
23 Jul 2026	Form 4: Reich Kristian, Chief Scientific Officer Sold 50,000 shares ($1M) · Sold 2,448 shares ($49K)
21 Jul 2026	Form 4: Reich Kristian, Chief Scientific Officer Sold 43,700 shares ($878K)
20 Jul 2026	Form 4: Reich Kristian, Chief Scientific Officer Sold 16,105 shares ($322K)
15 Jul 2026	144
15 Jul 2026	8-K: Other Events
13 Jul 2026	Form 4: Santos da Silva Jorge, Director Sold 33,936 shares ($679K) · Sold 68,289 shares ($1.37M)
02 Jul 2026	Form 4: Santos da Silva Jorge, Director Sold 47,775 shares ($957K)
30 Jun 2026	144
29 Jun 2026	SCHEDULE 13D/A
25 Jun 2026	8-K: Entry into a Material Definitive Agreement
24 Jun 2026	PROSPECTUS SUPPLEMENT

Comments